| 1 |
Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis [J]. Aliment Pharmacol Ther, 2014, 39(7): 660-671.
|
| 2 |
Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease [J]. Aliment Pharmacol Ther, 2014, 39(12): 1349-1362.
|
| 3 |
Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease [J]. J Gastroenterol, 2018, 53(3): 305-353.
|
| 4 |
Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment [J]. J Crohns Colitis, 2020, 14(1): 4-22.
|
| 5 |
Ran Z, Wu K, Matsuoka K, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia [J]. J Gastroenterol Hepatol, 2021, 36(3): 637-645.
|
| 6 |
Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis [J]. Gastroenterology, 2020, 158(5): 1450-1461.
|
| 7 |
Amiot A, Bouguen G, Bonnaud G, et al. French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus [J]. Dig Liver Dis, 2021, 53(1): 35-43.
|
| 8 |
Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [J]. Gut, 2019, 68(Suppl 3): s1-s106.
|
| 9 |
Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults [J]. Am J Gastroenterol, 2019, 114(3): 384-413.
|
| 10 |
中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2018年,北京) [J].中华消化杂志, 2018, 38(5): 292-311.
|
| 11 |
Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management [J]. J Crohns Colitis, 2017, 11(1): 3-25.
|
| 12 |
Torres J, Caprioli F, Katsanos KH, et al. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases [J]. J Crohns Colitis, 2016, 10(12): 1385-1394.
|
| 13 |
Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease [J]. J Crohns Colitis, 2016, 10(3): 239-254.
|
| 14 |
中华医学会儿科学分会消化学组,中华医学会儿科学分会临床营养学组.儿童炎症性肠病诊断和治疗专家共识[J].中华儿科杂志, 2019, 57(7): 501-507.
|
| 15 |
Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease [J]. J Crohns Colitis, 2014, 8(10): 1179-1207.
|
| 16 |
Gionchetti P, Dignass A, Danese S, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations [J]. J Crohns Colitis, 2017, 11(2): 135-149.
|
| 17 |
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition [J]. J Pediatr Gastroenterol Nutr, 2018, 67(2): 292-310.
|
| 18 |
Ng SC. Emerging leadership lecture: Inflammatory bowel disease in Asia: emergence of a "Western" disease [J]. J Gastroenterol Hepatol, 2015, 30(3): 440-445.
|
| 19 |
Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment [J]. Intest Res, 2018, 16(1): 4-16.
|
| 20 |
Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management [J]. J Gastroenterol Hepatol, 2018, 33(1): 30-36.
|
| 21 |
中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版) [J].实用肝脏病杂志, 2020, 23(1): S9-S32.
|
| 22 |
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance [J]. Hepatology, 2018, 67(4): 1560-1599.
|
| 23 |
杨红,冉志华,刘玉兰,等.炎症性肠病合并机会性感染专家共识意见[J].中华消化杂志, 2017, 37(4): 217-226.
|
| 24 |
Waljee AK, Higgins PDR, Jensen CB, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study [J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 276-284.
|
| 25 |
Cosnes J. What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy? [J]. Dig Dis, 2017, 35(1-2): 50-55.
|
| 26 |
Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease-algorithm for practical management [J]. Aliment Pharmacol Ther, 2016, 43(1): 30-51.
|
| 27 |
Peeters H, Louis E, Baert F, et al. Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab [J]. Acta Gastroenterol Belg, 2018, 81(1): 15-21.
|
| 28 |
Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed [J]. Aliment Pharmacol Ther, 2015, 41(7): 613-623.
|
| 29 |
Pagnini C, Siakavellas SI, Bamias G. Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients [J]. Gastroenterol Res Pract, 2018: 6317057.
|
| 30 |
Bodini G, Giannini EG, Savarino V, et al. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease [J]. Dig Liver Dis, 2018, 50(5): 452-456.
|
| 31 |
中华医学会消化病学分会炎症性肠病学组.中国炎症性肠病治疗药物监测专家共识意见[J].中华炎性肠病杂志, 2018, 2(4): 253-259.
|
| 32 |
Pouillon L, Ferrante M, Van Assche G, et al. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab [J]. Clin Gastroenterol Hepatol, 2018, 16(8): 1276.e1271-1283.e1271.
|
| 33 |
Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease [J]. Aliment Pharmacol Ther, 2017, 45(7): 933-940.
|
| 34 |
D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? [J]. Am J Gastroenterol, 2011, 106(2): 199-212; quiz 213.
|
| 35 |
Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy [J]. Gastroenterology, 2016, 150(3): 734.e731-757.e731.
|
| 36 |
上海市疾病预防控制中心,杭州市疾病预防控制中心,苏州市疾病预防控制中心,等.特殊健康状态儿童预防接种专家共识之十九——免疫抑制剂与预防接种[J].中国实用儿科杂志, 2019, 34(5): 335-336.
|
| 37 |
中华医学会炎症性肠病学组.抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017) [J].中华消化杂志, 2017, 37(9): 577-580.
|
| 38 |
Rutgeerts P, Assche GV, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial [J]. Gastroenterology, 2012, 142(5): 1102-1111.
|
| 39 |
Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE [J]. Aliment Pharmacol Ther, 2013, 38(10): 1236-1247.
|
| 40 |
Loftus EV, Reinisch W, Panaccione R, et al. Adalimumab effectiveness up to six years in adalimumab-naïve patients with Crohn's disease: results of the PYRAMID registry [J]. Inflamm Bowel Dis, 2019, 25(9): 1522-1531.
|
| 41 |
Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3 [J]. Am J Gastroenterol, 2014, 109(11): 1771-1780.
|
| 42 |
Matsumoto T, Motoya S, Watanabe K, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial [J]. J Crohns Colitis, 2016, 10(11): 1259-1266.
|
| 43 |
Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group [J]. Gastroenterology, 2019, 156(5): 1508-1524.
|
| 44 |
Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2 [J]. J Crohns Colitis, 2018, 12(5): 621-626.
|
| 45 |
Vermeire S, Loftus EV Jr, Colombel JF, et al. Long-term Efficacy of Vedolizumab for Crohn's Disease [J]. J Crohns Colitis, 2017, 11(4): 412s-424s.
|
| 46 |
Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease [J]. Gut, 2017, 66(5): 839-851.
|
| 47 |
Singh S, Dulai PS, Vande Casteele N, et al. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases [J]. Aliment Pharmacol Ther, 2019, 50(8): 848-857.
|
| 48 |
Yzet C, Diouf M, Singh S, et al. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-Analysis [J]. Clin Gastroenterol Hepatol, 2021, 19(4): 668.e8-679.e8.
|
| 49 |
Ribaldone DG, Pellicano R, Vernero M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis [J]. Scand J Gastroenterol, 2019, 54(4): 407-413.
|
| 50 |
Shashi P, Gopalakrishnan D, Parikh MP, et al. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study [J]. Gastroenterol Rep (Oxf), 2019, 8(4): 306-311.
|
| 51 |
Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease [J]. N Engl J Med, 2016, 375(20): 1946-1960.
|
| 52 |
Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease [J]. J Crohns Colitis, 2020, 14(1): 23-32.
|
| 53 |
Sandborn WJ, Rutgeerts P, Lynch J, et al. S0645 Efficacy and Safety of Ustekinumab for Crohn's Disease Through 5 Years: Final Results From the IM-UNITI Long-Term Extension [J]. Am J Gastroenterol, 2020, 8(8): S323-S324.
|
| 54 |
Engel T, Yung DE, Ma C, et al. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence [J]. Dig Liver Dis, 2019, 51(9): 1232-1240.
|
| 55 |
Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID [J]. Am J Gastroenterol, 2020, 115(11): 1812-1820.
|
| 56 |
Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn's disease: results of the ICC Registry, a nationwide prospective observational cohort study [J]. J Crohns Colitis, 2020, 14(1): 33-45.
|
| 57 |
Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature [J]. Scand J Gastroenterol, 2021, 56(1): 53-58.
|
| 58 |
Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis [J]. N Engl J Med, 2019, 381(13): 1201-1214.
|
| 59 |
Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy [J]. Aliment Pharmacol Ther, 2020, 52(11-12): 1658-1675.
|
| 60 |
Battat R, Kopylov U, Bessissow T, et al. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease [J]. Clin Gastroenterol Hepatol, 2017, 15(9): 1427.e2-1434.e2.
|
| 61 |
Yzet C, Diouf M, Singh S, et al. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis [J]. Clin Gastroenterol Hepatol, 2021, 19(4): 668.e8-679.e8.
|
| 62 |
Gisbert JP, Chaparro M. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review [J]. Drugs, 2020, 80(11): 1085-1100.
|